1)日本呼吸器学会 COPDガイドライン第6版作成委員会(編):COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン第6版,メディカルレビュー社,2022
2)日本アレルギー学会喘息ガイドライン専門部会(監),「喘息予防・管理ガイドライン2021」作成委員(作成):喘息予防・管理ガイドライン2021,協和企画,2021
3)Lipson DA, et al:Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 378:1671-1680, 2018
4)Jadwiga AW, et al:Indacaterol—Glycopyrronium versus Salmeterol—Fluticasone for COPD. N Engl J Med 374:2222-2234, 2016
5)Magnussen H, et al:Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 371:1285-1294, 2014
6)Calverley PM, et al:Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775-789, 2007
7)Molimard M, et al:Chronic obstructive pulmonary disease exacerbation and inhaler device handling;Real-life assessment of 2935 patients. Eur Respir J 49:1-7, 2017
8)岩永賢司,他:高齢者喘息.日内会誌102:1343-1351, 2013
9)Gibson PG, et al:Asthma in older adults. Lancet 376:803-813, 2010
). J Aerosol Med Pulm Drug Deliv 28:498-506, 2015
11)Marengoni A, et al:The relationship between COPD and frailty;A systematic review and meta-analysis of observational studies. Chest 154:21-40, 2018
12)Halpin DM, et al:INTREPID;Single-versus multiple-inhaler triple therapy for COPD in usual clinical practice. ERJ Open Res 7:00950-2020, 2021